XML 14 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Preferred Stock
Series A
Preferred Stock
Series D
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Accumulated Other Comprehensive Income
Due from Shareholders
Total Onconetix Equity (Deficit)
Non- controlling Interest
Total
Balance at Dec. 31, 2023   $ 49,429,037 $ (625,791) $ (56,786,194) $ 2,380,920 $ (5,602,028) $ 7,006,504 $ 1,404,476
Balance (in Shares) at Dec. 31, 2023 3,000   6,703                
Balance (in Shares) at Dec. 31, 2023         (152)            
Stock-based compensation expense   23,865 23,865 28,785 52,650
Foreign currency translation adjustment   (4,991,144) (4,991,144) (4,991,144)
Change in pension benefit obligation   154,678 154,678 154,678
Net loss   (11,118,572) (11,118,572) (11,118,572)
Balance at Mar. 31, 2024   49,452,902 $ (625,791) (67,904,766) (2,455,546) (21,533,201) 7,035,289 (14,497,912)
Balance (in Shares) at Mar. 31, 2024 3,000   6,703                
Balance (in Shares) at Mar. 31, 2024         (152)            
Balance at Dec. 31, 2023   49,429,037 $ (625,791) (56,786,194) 2,380,920 (5,602,028) 7,006,504 1,404,476
Balance (in Shares) at Dec. 31, 2023 3,000   6,703                
Balance (in Shares) at Dec. 31, 2023         (152)            
Net loss                     (29,252,681)
Balance at Sep. 30, 2024   $ 1 119,563,951 $ (625,791) (86,038,875) 1,012,557 33,911,843 7,110,777 41,022,620
Balance (in Shares) at Sep. 30, 2024   97,938                
Balance (in Shares) at Sep. 30, 2024         (152)            
Balance at Mar. 31, 2024   49,452,902 $ (625,791) (67,904,766) (2,455,546) (21,533,201) 7,035,289 (14,497,912)
Balance (in Shares) at Mar. 31, 2024 3,000   6,703                
Balance (in Shares) at Mar. 31, 2024         (152)            
Restricted stock forfeitures  
Restricted stock forfeitures (in Shares)     (3)                
Exercise of stock options   163 163 163
Exercise of stock options (in Shares)     4                
Stock-based compensation expense   (47,478) (47,478) 46,703 (775)
Foreign currency translation adjustment   110,000 110,000 110,000
Change in pension benefit obligation   (33,406) (33,406) (33,406)
Net loss   (14,306,704) (14,306,704) (14,306,704)
Balance at Jun. 30, 2024   49,405,587 $ (625,791) (82,211,470) (2,378,952) (35,810,626) 7,081,992 (28,728,634)
Balance (in Shares) at Jun. 30, 2024 3,000   6,704                
Balance (in Shares) at Jun. 30, 2024         (152)            
Issuance of common stock and warrants from exercise of preferred investment options   765,029 765,029 765,029
Issuance of common stock and warrants from exercise of preferred investment options (in Shares)     2,193                
Grant and immediate exercise of warrants   6,155 6,155 6,155
Grant and immediate exercise of warrants (in Shares)     1,812                
Issuance of shares in connection with subscription liability   5,134,247 5,134,247 5,134,247
Issuance of shares in connection with subscription liability (in Shares)     6,040                
Conversion of Series A shares to common stock upon reverse split  
Conversion of Series A shares to common stock upon reverse split (in Shares) (3,000)   1,679                
Conversion of Series B shares to common stock upon reverse split   $ 1 64,236,084 64,236,085 64,236,085
Conversion of Series B shares to common stock upon reverse split (in Shares)     79,315                
Stock-based compensation expense   16,849 16,849 28,785 45,634
Issuance of restricted common stock  
Issuance of restricted common stock (in Shares)     195                
Foreign currency translation adjustment     3,488,514 3,488,514 3,488,514
Change in pension benefit obligation   (97,005) (97,005) (97,005)
Net loss   (3,827,405) (3,827,405) (3,827,405)
Balance at Sep. 30, 2024   $ 1 119,563,951 $ (625,791) (86,038,875) 1,012,557 33,911,843 7,110,777 41,022,620
Balance (in Shares) at Sep. 30, 2024   97,938                
Balance (in Shares) at Sep. 30, 2024         (152)            
Balance at Dec. 31, 2024   $ 1 127,825,743 $ (625,791) (115,683,621) (2,723,397) (250,308) 8,542,627 $ 8,542,627
Balance (in Shares) at Dec. 31, 2024   138,422                
Balance (in Shares) at Dec. 31, 2024         (152)           152
Issuance of common stock in connection with the ELOC   $ 3 4,776,306 250,308 5,026,617 $ 5,026,617
Issuance of common stock in connection with the ELOC (in Shares)     294,194                
Stock-based compensation expense   29,256 29,256 29,256
Redemption of Series C Preferred Stock   (1,170,091) (1,170,091) (1,170,091)
Foreign currency translation adjustment   141,048 141,048 141,048
Change in pension benefit obligation   (30,779) (30,779) (30,779)
Net loss   (8,545,885) (8,545,885) (8,545,885)
Balance at Mar. 31, 2025   $ 4 132,631,305 $ (625,791) (125,399,597) (2,613,128) 3,992,793 3,992,793
Balance (in Shares) at Mar. 31, 2025   432,616                
Balance (in Shares) at Mar. 31, 2025         (152)            
Balance at Dec. 31, 2024   $ 1 127,825,743 $ (625,791) (115,683,621) (2,723,397) (250,308) 8,542,627 $ 8,542,627
Balance (in Shares) at Dec. 31, 2024   138,422                
Balance (in Shares) at Dec. 31, 2024         (152)           152
Net loss                     $ (19,702,029)
Balance at Sep. 30, 2025   $ 15 141,431,240 $ (625,791) (136,884,245) (547,098) 3,374,121 $ 3,374,121
Balance (in Shares) at Sep. 30, 2025   16,325 1,560,820                
Balance (in Shares) at Sep. 30, 2025         (152)           152
Balance at Mar. 31, 2025   $ 4 132,631,305 $ (625,791) (125,399,597) (2,613,128) 3,992,793 $ 3,992,793
Balance (in Shares) at Mar. 31, 2025   432,616                
Balance (in Shares) at Mar. 31, 2025         (152)            
Issuance of common stock in connection with the ELOC   $ 4 1,365,034 1,365,038 1,365,038
Issuance of common stock in connection with the ELOC (in Shares)     335,123                
Stock-based compensation expense   30,982 30,982 30,982
Cash in lieu of shares   (926) (926) (926)
Cash in lieu of shares (in Shares)     (127)                
Redemption of Series C Preferred Stock   (328,504) (328,504) (328,504)
Settlement of subscription agreement liability   $ 2 995,036 995,038 995,038
Settlement of subscription agreement liability (in Shares)     241,514                
Foreign currency translation adjustment   1,882,464 1,882,464 1,882,464
Change in pension benefit obligation   345,318 345,318 345,318
Net loss   (2,372,442) (2,372,442) (2,372,442)
Balance at Jun. 30, 2025   $ 10 135,021,431 $ (625,791) (128,100,543) (385,346) 5,909,761 5,909,761
Balance (in Shares) at Jun. 30, 2025   1,009,126                
Balance (in Shares) at Jun. 30, 2025         (152)            
Stock-based compensation expense   9,795 9,795 9,795
Issuance of restricted common stock  
Issuance of restricted common stock (in Shares)     2,472                
Issuance of Series D Preferred Stock   5,352,541 5,352,541 5,352,541
Issuance of Series D Preferred Stock (in Shares)   16,099                  
Conversion of Series C Preferred shares to common stock   $ 5 801,246 801,251 801,251
Conversion of Series C Preferred shares to common stock (in Shares)     544,409                
Exchange of Series C Preferred Stock to Series D Preferred Stock   246,227 246,227 246,227
Exchange of Series C Preferred Stock to Series D Preferred Stock (in Shares)   244                  
Conversion of Series D Preferred Stock to common stock  
Conversion of Series D Preferred Stock to common stock (in Shares)   (18) 4,878                
Cancellation of restricted common stock  
Cancellation of restricted common stock (in Shares)     (65)                
Foreign currency translation adjustment   (502,651) (502,651) (502,651)
Change in pension benefit obligation   340,899 340,899 340,899
Net loss   (8,783,702) (8,783,702) (8,783,702)
Balance at Sep. 30, 2025   $ 15 $ 141,431,240 $ (625,791) $ (136,884,245) $ (547,098) $ 3,374,121 $ 3,374,121
Balance (in Shares) at Sep. 30, 2025   16,325 1,560,820                
Balance (in Shares) at Sep. 30, 2025         (152)           152